Neurologic diseases and neurogenetics

Antonio Martinez Yelamos

PRINCIPAL INVESTIGATORS
  • Serge Jauma Classen
  • Monica Povedano Panades
  • Joan Prat Rojo
  • Sergio Martínez Yélamos
  • Jordi Gascon Bayarri
  • Cristina Sanchez Castañeda
  • Lucía Aja Rodríguez
  • Matilde Calopa Garriga
  • Pere Cardona Portela
  • Merçè Falip Centellas
  • Julia Miró Lladó
CLINICAL RESEARCHERS
  • Sara Yagüe Jimeno
  • Mariano Huerta Villanueva
  • Laura Bau Vila
  • Elisabet Matas Martín
  • Pere Domènech Santasusana
  • Misericordia Veciana De Las Heras
  • Lucia Maria Romero Pinel
  • Jaume Campdelacreu Fumado
  • Dolors Dot Bach
  • Isabel Fernández Conejero
  • Elisabet Romero Gangonells
  • Laura González Mera
  • Maria Isabel Leon Moreno
  • Raúl Domínguez Rubio
  • Andres Julian Paipa Merchan
  • Pablo Arroyo Pereiro
  • Blanca Lara Rodríguez
  • Velina Nedkova Hristova
POSTDOCTORAL RESEARCHERS
  • Pol Andres Benito
PREDOCTORAL RESEARCHERS
  • Silvia Muñoz Quiñones
  • Albert Muñoz Vendrell
  • Carla Marco Cazcarra
  • Sergio Roca Pereira
  • Roser Gomez Llopico
SCIENTIFIC SUPPORT
  • Gisela Zamorano Garcia
  • Sheila Álvarez Fornieles
  • Abdelilah Assialioui Essanhaji
MANAGEMENT SUPPORT
  • Susana Pobla Müller
  • José Luis Moreno Morejón
  • Cristina Terrafeta Pastor
Neuroscience
Neuroscience

Scientific production

51

PAPERS

Average IF: 11,169

17

LED PAPERS

Average IF: 4,456

14 PUBLICATIONS IN FIRST DECILE

29 PUBLICATIONS IN FIRST QUARTILE

32 PUBLICATIONS IN OPEN ACCESS

Selected publications

  • Muñoz Vendrell,A;Campoy,S;Caronna,E;Alpuente,A;Torres Ferrus,M;Nieves Castellanos,C;Olivier,M et al, Effectiveness and safety of anti-CGRP monoclonal antibodies in patients over 65 years: a real-life multicentre analysis of 162 patients., J. Headache Pain, 2023;24(1):63-63, doi:10.1186/s10194-023-01585-2
  • Arroyo Pereiro,P;García Serrano,L;Morandeira,F;Urban,B;Mas,V;Framil,M;León,I et al, Kappa free light chains index in multiple sclerosis very long-term prognosis, Front. Immunol., 2023;141223514-1223514, doi:10.3389/fimmu.2023.1223514
  • Van Daele,SH;Moisse,M;van Vugt,J;Zwamborn,R;van der Spek,R;van Rheenen,W;Van Eijk,K et al, Genetic variability in sporadic amyotrophic lateral sclerosis., Brain, 2023;00(9):1-10, doi:10.1093/brain/awad120
  • Martakis,K;Claassen,J;Gascon Bayari,J;Goldschagg,N;Hahn,A;Hassan,A;Hennig,A et al, Efficacy and Safety of N-Acetyl-l-Leucine in Children and Adults With GM2 Gangliosidoses, Neurology, 2023;100(10):1072-1083, doi:10.1212/WNL.0000000000201660
  • Sarraj,A;Hassan,AE;Abraham,MG;Ortega Gutierrez,S;Kasner,SE;Hussain,MS;Chen,MC et al, Trial of Endovascular Thrombectomy for Large Ischemic Strokes, N. Engl. J. Med., 2023;388(14):1259-1271, doi:10.1056/NEJMoa2214403

Research highlights

PROJECTS

3 Granted competitive projects
2 Ongoing competitive projects

4 Started clinical trials
55 Ongoing clinical trials
8 Ongoing non competitive projects

INNOVATION

1 Patent
1 License

PUBLISHED WORKS

1 Clinical guideline

NETWORKS

TRICALS
RETICS- REEM
CSUR

XUEC
ENCALS
ERN

Selected projects

  • MCI22004. Clinical trial to evaluate the administration of ApTOLL in ambulances and the neuroprotective effect in stroke patients. RACETOLL. Ministerio de Ciencia e Innovación. Budget: 487.992,8€. 2022-2025. PI: Cardona Portela, Pere.
  • MCI23008. NexTOLL: A Phase IIb Clinical trial to the evaluate neuroprotective effect of ApTOLL in stroke patients. Ministerio de Ciencia e Innovación. Budget: 485.715,5€. 2023-2026. PI: Cardona Portela, Pere.
  • INT23017. EPIDEMIOLOGICAL STUDY OF ALS IN COLOMBIA (SOUTH AMERICA) AND ETHIOPIA
    (AFRICA). ALS Society of Canada ALS CAD. Budget: 65.802,5€. 2024-2025. PI: POVEDANO PANADES, MONICA.
  • HUB-NEU-2019-01. Ensayo clínico de eficacia y seguridad de efavirenz en pacientes diagnosticados de Niemann-Pick C del adulto con deterioro cognitivo : Eudra CT 2019-004498-18. Fundación Niemann-Pick España. Budget: 80.000€. 2022-2024. PI: Gascón Bayarri, Jordi.
  • 21ACL033. ESTUDIO DE FASE III, MULTICÉNTRICO, ALEATORIZADO, DOBLE CIEGO, CON DOBLE ENMASCARAMIENTO Y DE GRUPOS PARALELOS PARA EVALUAR LA EFICACIA Y LA SEGURIDAD FENEBRUTINIB EN COMPARACIÓN CON TERIFLUNOMIDA EN PACIENTES ADULTOS ESCLEROSIS MÚLTIPLE RECURRENTE (EMR). Roche Farma, S.A. Budget: 112.560€. 2021- . PI: Martínez Yélamos, Sergio.